Spruce Street Capital LP Invests $8.22 Million in SAB Biotherapeutics, Inc. $SABS

Spruce Street Capital LP purchased a new position in shares of SAB Biotherapeutics, Inc. (NASDAQ:SABS) during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 2,198,502 shares of the company’s stock, valued at approximately $8,222,000. SAB Biotherapeutics makes up about 2.7% of Spruce Street Capital LP’s investment portfolio, making the stock its 13th largest position. Spruce Street Capital LP owned 4.62% of SAB Biotherapeutics at the end of the most recent quarter.

Other large investors have also made changes to their positions in the company. State of Wyoming acquired a new position in shares of SAB Biotherapeutics during the fourth quarter worth $34,000. State Street Corp acquired a new position in shares of SAB Biotherapeutics during the fourth quarter worth $49,000. ADAR1 Capital Management LLC acquired a new position in shares of SAB Biotherapeutics during the third quarter worth $30,000. Fifth Lane Capital LP acquired a new position in shares of SAB Biotherapeutics during the fourth quarter worth $56,000. Finally, Dimensional Fund Advisors LP acquired a new position in shares of SAB Biotherapeutics during the third quarter worth $32,000. 7.82% of the stock is owned by institutional investors and hedge funds.

SAB Biotherapeutics Price Performance

Shares of SABS opened at $3.90 on Tuesday. The firm has a market capitalization of $298.19 million, a PE ratio of -1.85 and a beta of 0.54. The company has a debt-to-equity ratio of 0.01, a current ratio of 11.45 and a quick ratio of 11.45. SAB Biotherapeutics, Inc. has a 1-year low of $1.65 and a 1-year high of $6.60. The company’s fifty day moving average price is $3.70 and its 200-day moving average price is $3.85.

SAB Biotherapeutics (NASDAQ:SABS) last announced its quarterly earnings data on Tuesday, May 12th. The company reported ($0.35) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.15). On average, equities research analysts predict that SAB Biotherapeutics, Inc. will post -1.19 EPS for the current year.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on SABS. Citigroup began coverage on SAB Biotherapeutics in a research report on Friday, May 22nd. They set a “buy” rating and a $11.00 price target on the stock. Rodman & Renshaw reissued a “buy” rating and set a $13.00 price objective on shares of SAB Biotherapeutics in a report on Monday, May 11th. Zacks Research raised shares of SAB Biotherapeutics from a “strong sell” rating to a “hold” rating in a report on Monday, May 11th. Wall Street Zen lowered shares of SAB Biotherapeutics from a “hold” rating to a “sell” rating in a report on Saturday, March 14th. Finally, Chardan Capital boosted their price objective on shares of SAB Biotherapeutics from $12.00 to $14.00 and gave the company a “buy” rating in a report on Wednesday, March 11th. Eight research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $11.63.

SAB Biotherapeutics Company Profile

SAB Biotherapeutics, Inc is a clinical-stage biotechnology company headquartered in Sioux Falls, South Dakota, that focuses on developing fully human polyclonal antibody therapeutics. The company’s proprietary platform, known as Tc Bovine®, uses genetically engineered cattle to generate large quantities of human antibodies tailored to target specific infectious agents or disease-related antigens. This approach is designed to combine the broad-spectrum coverage of polyclonal antibody therapies with the scalability and consistency required for clinical development and commercial use.

The company’s lead programs are directed primarily at infectious diseases.